Clinical Trial: Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: A Multi-Center, Open Label, 24-Month Treatment Study to Establish the Safety, Tolerability, Efficacy, Pharmacokinetics of Canakinumab (Anti-IL-1 Beta Antibody) in Patients With NOMID / This study will examine whether a medicine called canakinumab is safe and effective for treating patients with neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurologic, cutaneous, articular (CINCA) syndrome. This disease can cause rash, joint deformities, brain inflammation, problems with the eyes and learning difficulties. Canakinumab is an experimental drug that inhibits the action of a protein produced by the body called interleukin 1, which is responsible for the symptoms in NOMID and also contributes to many other kinds of inflammatory diseases.

Patients 2 years of age and older with NOMID may be eligible for this study. Participants undergo the following procedures:

Screening Phase

• Medical history and review of medical records
• Blood tests
• Daily diary of symptoms and medicines take

Washout/Lead-in Phase

• Discontinuation of anakinra or other medications

Treatment Phase

• Injection of canakinumab under the skin every 8 weeks for 6 months
• Monitoring and evaluations during treatment, including:
• Quality-of-life questionnaires and daily diary
• Vital signs measurements (heartbeat, blood pressure, temperature)
• Blood tests
• Electrocardiogram
• Tuberculosis skin te
  

  Detailed Summary:

  This open-label study was designed to investigate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of canakinumab, a fully human anti-interleukin-1beta (anti-IL-1beta) monoclonal antibody, in patients with NOMID / CINCA syndrome. A total of 25 to 30 patients will be enrolled into the study. The study consists of two stages:

  In the first pilot stage it is planned to enroll 5 patients undergoing PK/PD assessments in blood and cerebrospinal fluid (CSF), and monitoring of efficacy (CNS relapse and inflammatory relapse) to confirm the dose and dosing regimen before enlarging the number of patients enrolled into the study. Up to 5 additional patients may be enrolled in this stage if the variability of the responses to treatment is high. Interim analyses will be conducted as required. Following Stage 1, a second confirmatory stage will be conducted, enrolling 20 additional patients. In this stage patients will be treated with the dose and dosing regimen based on the assessment of the efficacy profile in Stage 1 and exploratory PK/PD assessment. In each stage there will be a 3-week screening period to collect pre-treatment parameters, a run-in period (only for patients who discontinue anakinra), a baseline evaluation prior to each drug administration, a 24-week treatment period with fixed dosing of canakinumab, and a study completion visit. Patients whose body weight is greater than 40 kg will receive canakinumab 150 mg as a subcutaneous (s.c.) injection, and patients with a body weight less than or equal to 40 kg will receive canakinumab 2 mg/kg s.c. Patients will be administered canakinumab every 8 weeks and will undergo an observation period after each dose administration in order to evaluate the response to treatment. Patients who do not achieve complete remission following canakinumab injection in any treatment period will be re-dosed within Day 15 o
  Sponsor: Novartis Pharmaceuticals
  

  Current Primary Outcome: Inflammatory remission, CNS, peripheral blood [ Time Frame: 6 months with planned extension ]
  
  

  Original Primary Outcome: Inflammatory remission, CNS, peripheral blood
  
  

  Current Secondary Outcome: Biomarkers [ Time Frame: 6 months ]
  
  

  Original Secondary Outcome: Biomarkers
  
  Information By: Novartis
  

  Dates:
  Date Received: October 9, 2008
  Date Started: January 2009
  Date Completion:
  Last Updated: May 3, 2012
  Last Verified: May 2012